Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Core Scientific Inc (CORZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Core Scientific Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Core Scientific Inc trades at $23.63 (market cap $6.85B). The key difference: Core Scientific Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ACAD | CORZ | |
|---|---|---|
Market Cap | $4.49B | $6.85B |
Sector | Health | Technology |
52-Week High | $28.06 | $29.16 |
52-Week Low | $20.06 | $12.51 |
Enterprise Value | $3.69B | $7.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CORZ trades at $22.80, up 6.39% today, while showing bearish technical signals with a net cash outflow of $525.6M in 2025. The company is pivoting from Bitcoin mining to AI colocation, with Q1 2026 colocation revenue surging to $77.5M and gross margins of 57%. Despite missing earnings estimates for three consecutive quarters, analyst consensus remains strongly bullish with 86% buy ratings and a $33.43 price target.
The stock presents a high-risk, high-reward opportunity as the AI infrastructure transition accelerates. Near-term execution risks and negative profitability metrics contrast with substantial growth potential in the AI data center market. Wall Street optimism appears to outweigh current financial challenges, but investors should monitor cash flow improvements and contract execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →
